Adagene is a clinical-stage biotechnology company that discovers and develops antibody therapeutics for cancer treatment using its proprietary Distributed Platform technology, which comprises three distinct antibody discovery platforms: NEObody, SAFEbody, and POWERbody. The company generates revenues through licensing and collaboration agreements with third parties, though it has not yet commercialized any products or received regulatory approvals for any product candidates. Adagene operates through subsidiaries in China and the United States, conducting research and development activities, preclinical testing, and clinical trials with a pipeline of wholly-owned and out-licensed antibody candidates.